L.V. Kirkovsky
L.V. Kirkovsky has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- O. O. Rummo
Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
4 shared publications - A. E. Shcherba
State Institution “Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
3 shared publications - S. V. Korotkov
Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
3 shared publications - A.M. Fedaruk
ГУ «Минский научно-практический центр хирургии, трансплантологии и гематологии
2 shared publications - Dmitry Fedoruk
Department of Hepatology and Minimally Invasive Surgery, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology, 220087, Semashko st., 8, Minsk, Belarus
2 shared publications - К. И. Петренко (K. I. Petrenko)
ГУ «Минский НПЦ хирургии, трансплантологии и гематологии
2 shared publications
Latest Publications
- Open Access
- 22 September 2025
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 30 (3) , 31-38
Pancreatic cystic tumors: literature review and early surgical outcomes at a certain center
Aim. To analyze the outcomes of patients with pancreatic cystic tumors managed at a high-volume hepato-pancreatobiliary (HPB) surgery center.Materials and Methods. Between 2014 and 2025, a total of 386 pancreatic resections were performed, with 82 (21.24%) for pancreatic cystic tumors. The mean patient age was 51 ± 10.7 years, and 63.4% of the patients were female.Results. Of the patients who underwent surgical operations, 10 (12.1%) had branch-duct intraductal papillary mucinous neoplasms (IPMNs), and 13 (15.88%) had main-duct IPMNs. Additionally, 25 patients (30.53%) were treated for mucinous cystic neoplasms, 1 (1.21%) for a cystic neuroendocrine tumor, 21 (25.63%) for solid pseudopapillary neoplasms, and 12 (14.63%) for serous cystadenomas. A retrospective pathohistological analysis of 121 cases of pancreatic head cancer following pancreatoduodenectomy revealed that 31 patients (25.61%) had developed adenocarcinoma associated with mucinous ductal neoplasms of various types.Conclusion. Pancreatic cystic tumors exhibit variable biological behaviors, necessitating differential diagnosis and management.
- 22 September 2025
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 30 (3) , 31-38
Open AccessPancreatic cystic tumors: literature review and early surgical outcomes at a certain center
Aim. To analyze the outcomes of patients with pancreatic cystic tumors managed at a high-volume hepato-pancreatobiliary (HPB) surgery center.Materials and Methods. Between 2014 and 2025, a total of 386 pancreatic resections were performed, with 82 (21.24%) for pancreatic cystic tumors. The mean patient age was 51 ± 10.7 years, and 63.4% of the patients were female.Results. Of the patients who underwent surgical operations, 10 (12.1%) had branch-duct intraductal papillary mucinous neoplasms (IPMNs), and 13 (15.88%) had main-duct IPMNs. Additionally, 25 patients (30.53%) were treated for mucinous cystic neoplasms, 1 (1.21%) for a cystic neuroendocrine tumor, 21 (25.63%) for solid pseudopapillary neoplasms, and 12 (14.63%) for serous cystadenomas. A retrospective pathohistological analysis of 121 cases of pancreatic head cancer following pancreatoduodenectomy revealed that 31 patients (25.61%) had developed adenocarcinoma associated with mucinous ductal neoplasms of various types.Conclusion. Pancreatic cystic tumors exhibit variable biological behaviors, necessitating differential diagnosis and management.
- Open Access
- 30 September 2024
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 29 (3) , 70-80
Liver transplantation for unresectable Klatskin tumor: experience of two centers, first distant results
Aim. Evaluation of the first distant results of the combined experience of liver transplantation for unresectable portal cholangiocarcinoma from two large specialized clinical centers.Materials and methods. In total, 23 attempts at liver transplantation for unresectable Klatskin tumor were undertaken. Out of them, 10 were conducted at the A.M. Granov Russian Research Center for Radiology and Surgical Technologies (Granov Center), and 13 were conducted at the Minsk Scientific and Practical Center for Surgery, Transplantology, and Hematology (Minsk Center). The maximum tumor size was 5 and 3 cm in patients operated at the Granov and Minsk Centers, respectively. In the Granov Center, neoadjuvant therapy included a combination of endobiliary photodynamic therapy, regional and systemic chemotherapy. Patients were included in the waiting list only in cases of decreased tumor marker levels and in the absence of disease progression and acute cholangitis. In the Minsk Center, stereotactic radiotherapy was used for neoadjuvant treatment in the absence of active cholangitis; the first 3 patients underwent liver transplantation without prior neoadjuvant treatment.Results. Due to disease progression, six patients were excluded. In three patients at the Mink Center, the diagnosis was not morphologically confirmed after liver transplantation. A total of 14 liver transplantations were performed for unresectable hilar cholangiocarcinoma. After neoadjuvant treatment at the Granov Center, normalization of the CA19-9 marker was observed in four patients, its decrease by 3–4 times was observed in two patients. Liver transplantation was performed in six patients. The average time from the onset of treatment to transplantation was 9.1 months (6–14). Out of the six patients, one was alive for 34 months, with the median overall survival being 22.2 months. Progression was the cause of death in only one patient. Out of the three patients without neoadjuvant treatment at the Minsk Center, two were alive at 16 and 134 months without progression. One patient died after transplantation from disease progression at 24 months. Stereotactic radiotherapy achieved normalization of CA19-9 in four patients; its twofold reduction was observed in one patient. The average time from the onset of treatment to transplantation was six months (3–12). The average CA19-9 tumor marker level by the time of transplantation was 11.3 IU/mL. At 20–26 months, three patients were alive without evidence of disease progression; two patients died of progression after 9 and 59 months.Conclusion. Liver transplantation for unresectable portal cholangiocarcinoma after neoadjuvant treatment regardless of the methods used is highly promising in carefully selected recipients.
- 30 September 2024
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 29 (3) , 70-80
Open AccessLiver transplantation for unresectable Klatskin tumor: experience of two centers, first distant results
Aim. Evaluation of the first distant results of the combined experience of liver transplantation for unresectable portal cholangiocarcinoma from two large specialized clinical centers.Materials and methods. In total, 23 attempts at liver transplantation for unresectable Klatskin tumor were undertaken. Out of them, 10 were conducted at the A.M. Granov Russian Research Center for Radiology and Surgical Technologies (Granov Center), and 13 were conducted at the Minsk Scientific and Practical Center for Surgery, Transplantology, and Hematology (Minsk Center). The maximum tumor size was 5 and 3 cm in patients operated at the Granov and Minsk Centers, respectively. In the Granov Center, neoadjuvant therapy included a combination of endobiliary photodynamic therapy, regional and systemic chemotherapy. Patients were included in the waiting list only in cases of decreased tumor marker levels and in the absence of disease progression and acute cholangitis. In the Minsk Center, stereotactic radiotherapy was used for neoadjuvant treatment in the absence of active cholangitis; the first 3 patients underwent liver transplantation without prior neoadjuvant treatment.Results. Due to disease progression, six patients were excluded. In three patients at the Mink Center, the diagnosis was not morphologically confirmed after liver transplantation. A total of 14 liver transplantations were performed for unresectable hilar cholangiocarcinoma. After neoadjuvant treatment at the Granov Center, normalization of the CA19-9 marker was observed in four patients, its decrease by 3–4 times was observed in two patients. Liver transplantation was performed in six patients. The average time from the onset of treatment to transplantation was 9.1 months (6–14). Out of the six patients, one was alive for 34 months, with the median overall survival being 22.2 months. Progression was the cause of death in only one patient. Out of the three patients without neoadjuvant treatment at the Minsk Center, two were alive at 16 and 134 months without progression. One patient died after transplantation from disease progression at 24 months. Stereotactic radiotherapy achieved normalization of CA19-9 in four patients; its twofold reduction was observed in one patient. The average time from the onset of treatment to transplantation was six months (3–12). The average CA19-9 tumor marker level by the time of transplantation was 11.3 IU/mL. At 20–26 months, three patients were alive without evidence of disease progression; two patients died of progression after 9 and 59 months.Conclusion. Liver transplantation for unresectable portal cholangiocarcinoma after neoadjuvant treatment regardless of the methods used is highly promising in carefully selected recipients.
- Open Access
- 7 June 2022
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 27 (2) , 39-47
Evolution of approaches to portal hypertension syndrome and principles underlying treatment personalization
Aim. To analyze various strategies aimed at mitigating complications of the portal hypertension syndrome at the Minsk Scientific and Practical Center for Surgery, Transplantology, and Hematology.Material and methods. Patients who had undergone different types of treatment were retrospectively observed: shunt surgery to form portacaval anastomoses, transjugular portosystemic shunt placement, and liver transplantation. The following parameters were analyzed: incidence of complications, hospital mortality rate, survival rate, and perioperative indicators.Results. Since 1980, 131 shunt surgeries have been performed at the Center, while 880 liver transplantations and 232 transjugular portosystemic shunt placement procedures have been performed since 2008. Among 68 patients with compensated cirrhosis who had undergone shunt placement, no hospital mortality rate was reported, whereas in patients with Child-Pugh B cirrhosis and Child–Pugh C cirrhosis, it reached 19.5% and 87.5%, respectively. Following TIPS, the overall case mortality rate amounted to 9.9% (following TIPS prior to transplantation – 8.2%, following TIPS used as the final treatment – 12.8%). After liver transplantation, in-hospital mortality rate reached 7.7%.Conclusion. Over 50 years, the strategy for managing portal hypertension has undergone significant changes due to the establishment of institutions providing a complete cycle of all treatment measures for such patients. Patients suffering from the complications of the portal hypertension syndrome tend to receive the most effective treatment in hospitals having experience in rational conservative therapy, endovascular procedures, and transplantation.
- 7 June 2022
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 27 (2) , 39-47
Open AccessEvolution of approaches to portal hypertension syndrome and principles underlying treatment personalization
Aim. To analyze various strategies aimed at mitigating complications of the portal hypertension syndrome at the Minsk Scientific and Practical Center for Surgery, Transplantology, and Hematology.Material and methods. Patients who had undergone different types of treatment were retrospectively observed: shunt surgery to form portacaval anastomoses, transjugular portosystemic shunt placement, and liver transplantation. The following parameters were analyzed: incidence of complications, hospital mortality rate, survival rate, and perioperative indicators.Results. Since 1980, 131 shunt surgeries have been performed at the Center, while 880 liver transplantations and 232 transjugular portosystemic shunt placement procedures have been performed since 2008. Among 68 patients with compensated cirrhosis who had undergone shunt placement, no hospital mortality rate was reported, whereas in patients with Child-Pugh B cirrhosis and Child–Pugh C cirrhosis, it reached 19.5% and 87.5%, respectively. Following TIPS, the overall case mortality rate amounted to 9.9% (following TIPS prior to transplantation – 8.2%, following TIPS used as the final treatment – 12.8%). After liver transplantation, in-hospital mortality rate reached 7.7%.Conclusion. Over 50 years, the strategy for managing portal hypertension has undergone significant changes due to the establishment of institutions providing a complete cycle of all treatment measures for such patients. Patients suffering from the complications of the portal hypertension syndrome tend to receive the most effective treatment in hospitals having experience in rational conservative therapy, endovascular procedures, and transplantation.
- 24 December 2020
- Published by Vitebsk State Medical University in Novosti Khirurgii
- Vol. 28 (6) , 671-679
Bile Lactate as a Marker of Ballooning Degeneration of Hepatocytes and a Potential Criterion for Choosing a Method of Liver Transplant Preservation
Цель. Определить диагностическую ценность уровня лактата и других компонентов желчи донора как маркеров, позволяющих дать дополнительную оценку и объективизировать состояние трансплантата печени, оценить необходимость динамического кондиционирования, а также прогнозировать течение раннего послеоперационного периода. Материал и методы. С июля 2017 г. по ноябрь 2019 г. в ходе операции эксплантации выполнялся забор желчи из холедоха и биопсия паренхимы печени. Все трансплантаты были разделены на 2 группы в зависимости от пригодности к трансплантации. Группу 1 составили органы, которые были в дальнейшем трансплантированы, а группу 2 – органы, которые были признаны непригодными к пересадке. Проводился анализ КОС (кислотно-основного состояния) желчи доноров, а также морфологический анализ трансплантатов обоех групп. Результаты. Была определена достоверная взаимосвязь между уровнем лактата желчи доноров обоех групп (n=50) и уровнем баллонной дистрофии гепатоцитов (R=0,50, p=0,001). В тех случаях, где наблюдалась выраженная баллонная дистрофия, определялись достоверно более высокие уровни лактата в желчи доноров (1,9 [1,2; 2,55]) в сравнении с теми образцами, где она была не выражена (0,6 [0,3; 1,7]) (р=0,006). ROC-анализ позволил определить уровень лактата в желчи в 1 ммоль/л в качестве отрезной точки, при которой вероятность наличия выраженной баллонной дистрофии будет наибольшей (AUC= 0,830). В группе 1 получена достоверная ассоциация между уровнем лактата желчи доноров и АЛТ в пиковом значении (R=0,56, p=0,004) и на седьмые сутки после операции (R=0,53, p=0,01), а также уровнем МНО в пиковом значении (R=0,63, p=0,001). Заключение. Лактат желчи достоверно отражает степень баллонной дистрофии гепатоцитов и позволяет объективизировать состояние печени доноров, а также прогнозировать течение раннего послеоперационного периода. Уровень лактата желчи более 1 ммоль/л является потенциальным критерием для проведения оксигенированной машинной перфузии. Научная новизна статьи Изучена взаимосвязь между кислотно-основным составом желчи и морфологическими характеристиками трансплантатов печени. Впервые установлена взаимосвязь между уровнем лактата желчи доноров на этапе мультиорганного забора и баллонной дистрофией гепатоцитов, а также уровнем лактата желчи и лабораторными показателями реципиентов в раннем послеоперационном периоде. Определена диагностическая ценность лактата желчи как маркера баллонной дистрофии клеток печени.
- 24 December 2020
- Published by Vitebsk State Medical University in Novosti Khirurgii
- Vol. 28 (6) , 671-679
Bile Lactate as a Marker of Ballooning Degeneration of Hepatocytes and a Potential Criterion for Choosing a Method of Liver Transplant Preservation
Цель. Определить диагностическую ценность уровня лактата и других компонентов желчи донора как маркеров, позволяющих дать дополнительную оценку и объективизировать состояние трансплантата печени, оценить необходимость динамического кондиционирования, а также прогнозировать течение раннего послеоперационного периода. Материал и методы. С июля 2017 г. по ноябрь 2019 г. в ходе операции эксплантации выполнялся забор желчи из холедоха и биопсия паренхимы печени. Все трансплантаты были разделены на 2 группы в зависимости от пригодности к трансплантации. Группу 1 составили органы, которые были в дальнейшем трансплантированы, а группу 2 – органы, которые были признаны непригодными к пересадке. Проводился анализ КОС (кислотно-основного состояния) желчи доноров, а также морфологический анализ трансплантатов обоех групп. Результаты. Была определена достоверная взаимосвязь между уровнем лактата желчи доноров обоех групп (n=50) и уровнем баллонной дистрофии гепатоцитов (R=0,50, p=0,001). В тех случаях, где наблюдалась выраженная баллонная дистрофия, определялись достоверно более высокие уровни лактата в желчи доноров (1,9 [1,2; 2,55]) в сравнении с теми образцами, где она была не выражена (0,6 [0,3; 1,7]) (р=0,006). ROC-анализ позволил определить уровень лактата в желчи в 1 ммоль/л в качестве отрезной точки, при которой вероятность наличия выраженной баллонной дистрофии будет наибольшей (AUC= 0,830). В группе 1 получена достоверная ассоциация между уровнем лактата желчи доноров и АЛТ в пиковом значении (R=0,56, p=0,004) и на седьмые сутки после операции (R=0,53, p=0,01), а также уровнем МНО в пиковом значении (R=0,63, p=0,001). Заключение. Лактат желчи достоверно отражает степень баллонной дистрофии гепатоцитов и позволяет объективизировать состояние печени доноров, а также прогнозировать течение раннего послеоперационного периода. Уровень лактата желчи более 1 ммоль/л является потенциальным критерием для проведения оксигенированной машинной перфузии. Научная новизна статьи Изучена взаимосвязь между кислотно-основным составом желчи и морфологическими характеристиками трансплантатов печени. Впервые установлена взаимосвязь между уровнем лактата желчи доноров на этапе мультиорганного забора и баллонной дистрофией гепатоцитов, а также уровнем лактата желчи и лабораторными показателями реципиентов в раннем послеоперационном периоде. Определена диагностическая ценность лактата желчи как маркера баллонной дистрофии клеток печени.
- Open Access
- 4 June 2020
- Published by Grodno State Medical University in Hepatology and Gastroenterology
- Vol. 4 (1) , 28-33
THE METABOLISM OF GLUCOSE AS THE MAIN ENERGY SUBSTRATE OF HEPATOCYTES IN DIFFERENT METHODS OF LIVER PRESERVATION
МЕТАБОЛИЗМ ГЛЮКОЗЫ КАК ОСНОВНОГО ЭНЕРГЕТИЧЕСКОГО СУБСТРАТА ГЕПАТОЦИТОВ ПРИ РАЗНЫХ МЕТОДАХ КОНСЕРВАЦИИ ПЕЧЕНИ
- 4 June 2020
- Published by Grodno State Medical University in Hepatology and Gastroenterology
- Vol. 4 (1) , 28-33
Open AccessTHE METABOLISM OF GLUCOSE AS THE MAIN ENERGY SUBSTRATE OF HEPATOCYTES IN DIFFERENT METHODS OF LIVER PRESERVATION
МЕТАБОЛИЗМ ГЛЮКОЗЫ КАК ОСНОВНОГО ЭНЕРГЕТИЧЕСКОГО СУБСТРАТА ГЕПАТОЦИТОВ ПРИ РАЗНЫХ МЕТОДАХ КОНСЕРВАЦИИ ПЕЧЕНИ